SciCombinator

Discover the most talked about and latest scientific content & concepts.

Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine

OPEN The New England journal of medicine | 14 Nov 2017

SD Weisbord, M Gallagher, H Jneid, S Garcia, A Cass, SS Thwin, TA Conner, GM Chertow, DL Bhatt, K Shunk, CR Parikh, EO McFalls, M Brophy, R Ferguson, H Wu, M Androsenko, J Myles, J Kaufman and PM Palevsky
Abstract
Background Intravenous sodium bicarbonate and oral acetylcysteine are widely used to prevent acute kidney injury and associated adverse outcomes after angiography without definitive evidence of their efficacy. Methods Using a 2-by-2 factorial design, we randomly assigned 5177 patients at high risk for renal complications who were scheduled for angiography to receive intravenous 1.26% sodium bicarbonate or intravenous 0.9% sodium chloride and 5 days of oral acetylcysteine or oral placebo; of these patients, 4993 were included in the modified intention-to-treat analysis. The primary end point was a composite of death, the need for dialysis, or a persistent increase of at least 50% from baseline in the serum creatinine level at 90 days. Contrast-associated acute kidney injury was a secondary end point. Results The sponsor stopped the trial after a prespecified interim analysis. There was no interaction between sodium bicarbonate and acetylcysteine with respect to the primary end point (P=0.33). The primary end point occurred in 110 of 2511 patients (4.4%) in the sodium bicarbonate group as compared with 116 of 2482 (4.7%) in the sodium chloride group (odds ratio, 0.93; 95% confidence interval [CI], 0.72 to 1.22; P=0.62) and in 114 of 2495 patients (4.6%) in the acetylcysteine group as compared with 112 of 2498 (4.5%) in the placebo group (odds ratio, 1.02; 95% CI, 0.78 to 1.33; P=0.88). There were no significant between-group differences in the rates of contrast-associated acute kidney injury. Conclusions Among patients at high risk for renal complications who were undergoing angiography, there was no benefit of intravenous sodium bicarbonate over intravenous sodium chloride or of oral acetylcysteine over placebo for the prevention of death, need for dialysis, or persistent decline in kidney function at 90 days or for the prevention of contrast-associated acute kidney injury. (Funded by the U.S. Department of Veterans Affairs Office of Research and Development and the National Health and Medical Research Council of Australia; PRESERVE ClinicalTrials.gov number, NCT01467466 .).
Tweets*
2023
Facebook likes*
44
Reddit*
0
News coverage*
10
Blogs*
7
SC clicks
0
Concepts
Sodium chloride, Placebo, Kidney, 25th century, 3rd millennium, Nephrology, Renal physiology, Renal failure
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com